IP Library Granted Patent US 11,730,903
Granted Patent B2
US 11,730,903 · App. 16/664,588 · Granted Aug 22, 2023

Nasal drug delivery device

Inventors: John D. Hoekman (Seattle, WA); Michael Hite (Normandy Park, WA); Alan Brunelle (Woodinville, WA); Joel Relethford (Everett, WA); Rodney J. Y. Ho (Mercer Island, WA)
Assignee: Impel Pharmaceuticals Inc.
A61M15/08A61M11/02A61M2202/0468A61M2202/064A61M2205/073A61M2205/8225
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,730,903
App. No.
16/664,588
Granted
Aug 22, 2023
Kind
B2
Abstract

A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.

Claims (31)

1. A device for delivery of a compound to a nasal cavity, the device comprising:

an air compression chamber;

a manual pressure actuator that causes air to be released from the air compression chamber upon actuation;

a diffuser in communication with the air compression chamber;

a drug chamber in communication with the diffuser and a diffusion tube, the drug chamber configured to hold the compound and the diffusion tube allowing for the released air to bypass the compound; and

a nozzle in communication with the drug chamber, wherein air released from the air compression chamber is configured to flow through the diffuser to contact and propel the compound out of the nozzle forming a plume.

2. The device of claim 1 , wherein the manual pressure actuator further comprises a lock pin, wherein the lock pin is configured to maintain high pressure air in the air compression chamber.

3. The device of claim 1 , further comprising a trigger valve in communication with the air compression chamber such that when the trigger valve is rotated from an open state to a closed state, air in the air compression chamber is blocked from contacting the diffuser and propelling the compound out of the nozzle.

4. The device of claim 1 , wherein the manual pressure actuator comprises a piston.

5. The device of claim 1 , wherein the manual pressure actuator comprises a syringe.

6. The device of claim 1 , wherein the manual pressure actuator comprises a syrette.

7. The device of claim 1 , wherein the diffuser is heterogeneously porous or homogenously porous.

8. The device of claim 1 , wherein the compound is a drug or diagnostic agent.

9. The device of claim 8 , wherein the diagnostic agent is an imaging agent.

10. The device of claim 1 , wherein the diffuser is porous, the porous diffuser being a disk-shaped member including at least one conical shaped member having a distal aperture.

11. The device of claim 1 , wherein the diffuser is configured to act as a one-way check valve.

12. The device of claim 1 , wherein the diffuser extends into the compound in the drug chamber.

13. A device for delivering a compound to a nasal cavity, the device comprising:

an air compression chamber;

a manual pressure actuator comprising a lock pin, the manual pressure actuator configured to release air from the air compression chamber, the lock pin configured to maintain high pressure air in the air compression chamber;

a trigger valve configured to be in communication with the air compression chamber such that when the trigger valve is rotated from an open state to a closed state, air in the air compression chamber is blocked from exiting the air compression chamber;

a diffuser in communication with the trigger valve;

a drug chamber in communication with the diffuser and a diffusion tube, the drug chamber configured to hold the compound and the diffusion tube allowing for the released air to bypass the compound; and

a nozzle in communication with the drug chamber, wherein air released from the air compression chamber is configured to flow through the diffuser to contact and propel the compound out of the nozzle forming a plume.

14. The device of claim 13 , wherein the manual pressure actuator further comprises a piston.

15. The device of claim 13 , wherein the manual pressure actuator further comprises a syringe.

16. The device of claim 13 , wherein the manual pressure actuator further comprises a syrette.

17. The device of claim 13 , wherein the diffuser is heterogeneously porous or homogenously porous.

18. The device of claim 13 , wherein the diffuser is configured to act as a one-way check valve.

19. The device of claim 13 , wherein the diffuser is porous, the porous diffuser being a disk-shaped member including at least one conical shaped member having a distal aperture.

20. The device of claim 13 , wherein the diffuser extends into the compound in the drug chamber.

Assignments (12)
SECURITY INTEREST Recorded Jun 5, 2025
From: WOODWARD SPECIALTY LLC
To: ALTER DOMUS (US) LLC
Reel/Frame 071324/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2024
From: JN BIDCO LLC
To: WOODWARD SPECIALTY LLC
Reel/Frame 067062/0344 →
SECURITY INTEREST Recorded Mar 20, 2024
From: JN BIDCO LLC
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 066837/0144 →
RELEASE OF SECURITY INTEREST Recorded Feb 28, 2024
From: OAKTREE FUND ADMINISTRATION, LLC
To: IMPEL PHARMACEUTICALS, INC.
Reel/Frame 066699/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2024
From: IMPEL PHARMACEUTICALS INC.
To: JN BIDCO LLC
Reel/Frame 066601/0479 →
CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVAL OF APPLICATION NUMBERS 12866448 AND APLICATION NUMBER 14292481 PREVIOUSLY RECORDED AT REEL: 059790 FRAME: 0722. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 4, 2022
From: IMPEL NEUROPHARMA, INC.
To: IMPEL PHARMACEUTICALS INC.
Reel/Frame 059855/0252 →
CHANGE OF NAME Recorded Apr 25, 2022
From: IMPEL NEUROPHARMA, INC.
To: IMPEL PHARMACEUTICALS INC.
Reel/Frame 059790/0722 →
SECURITY INTEREST Recorded Mar 17, 2022
From: IMPEL NEUROPHARMA, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059300/0433 →
SECURITY INTEREST Recorded Mar 17, 2022
From: IMPEL NEUROPHARMA, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 059300/0390 →
RELEASE OF SECURITY INTEREST Recorded Jul 6, 2021
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: IMPEL NEUROPHARMA, INC.
Reel/Frame 056758/0495 →
SECURITY INTEREST Recorded Nov 5, 2020
From: IMPEL NEUROPHARMA, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 054287/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2019
From: HOEKMAN, JOHN D.; HITE, MICHAEL; BRUNELLE, ALAN; RELETHFORD, JOEL; HO, RODNEY J.Y.
To: IMPEL NEUROPHARMA, INC.
Reel/Frame 050961/0234 →
Continuity (8)
Continuation 15338097 · Oct 28, 2016
Continuation 14017048 · Sep 3, 2013
Continuation PCTUS2012027754 · Mar 5, 2012
Provisional Application 61498974 · Jun 20, 2011
Provisional Application 61484025 · May 9, 2011
Provisional Application 61451935 · Mar 11, 2011
Provisional Application 61449008 · Mar 3, 2011
Related Publication 20200078544A1 · Mar 12, 2020